Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Super-Enhancer Hypermutation Alters Oncogene Expression in B-cell Lymphoma

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE207395 | GEO | 2022/07/03

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Super-enhancer hypermutation alters oncogene expression in B cell lymphoma.

Project description:Diffuse large B cell lymphoma (DLBCL) is the most common B cell non-Hodgkin lymphoma and remains incurable in around 40% of patients. Efforts to sequence the coding genome identified several genes and pathways that are altered in this disease, including potential therapeutic targets1-5. However, the non-coding genome of DLBCL remains largely unexplored. Here we show that active super-enhancers are highly and specifically hypermutated in 92% of samples from individuals with DLBCL, display signatures of activation-induced cytidine deaminase activity, and are linked to genes that encode B cell developmental regulators and oncogenes. As evidence of oncogenic relevance, we show that the hypermutated super-enhancers linked to the BCL6, BCL2 and CXCR4 proto-oncogenes prevent the binding and transcriptional downregulation of the corresponding target gene by transcriptional repressors, including BLIMP1 (targeting BCL6) and the steroid receptor NR3C1 (targeting BCL2 and CXCR4). Genetic correction of selected mutations restored repressor DNA binding, downregulated target gene expression and led to the counter-selection of cells containing corrected alleles, indicating an oncogenic dependency on the super-enhancer mutations. This pervasive super-enhancer mutational mechanism reveals a major set of genetic lesions deregulating gene expression, which expands the involvement of known oncogenes in DLBCL pathogenesis and identifies new deregulated gene targets of therapeutic relevance.

| S-EPMC9583699 | biostudies-literature

Genetic dissection of the Î±-globin super-enhancer

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2016-06-02 | E-GEOD-78835 | biostudies-arrayexpress

Super-Enhancer Hypermutation Alters Oncogene Expression in B-cell Lymphoma

Project description:Super-Enhancer Hypermutation Alters Oncogene Expression in B-cell Lymphoma

| PRJNA855230 | ENA

INO80 governs super-enhancer-mediated oncogenic transcription and tumor growth in melanoma

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2016-07-07 | E-GEOD-82334 | biostudies-arrayexpress

Tex10 Coordinates Epigenetic Control of Super-Enhancer Activity for Pluripotency and Reprogramming

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2015-05-06 | E-GEOD-66736 | biostudies-arrayexpress

Super-Enhancer-Associated Aortic Valve Stenosis Risk Locus 1p21.2 Alters NFATC2 Binding Site and Promotes Fibrogenesis